scholarly journals Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies

mBio ◽  
2020 ◽  
Vol 11 (2) ◽  
Author(s):  
Tania Rivera-Hernandez ◽  
Mira Syahira Rhyme ◽  
Amanda J. Cork ◽  
Scott Jones ◽  
Celia Segui-Perez ◽  
...  
Keyword(s):  
Immune Responses ◽  
Protective Efficacy ◽  
M Protein ◽  
Invasive Infection ◽  
Protein Vaccine ◽  
Protein Antigens ◽  
Igg Antibody ◽  
Water Emulsion ◽  
Group A ◽  
Type Response

ABSTRACT Recent global advocacy efforts have highlighted the importance of development of a vaccine against group A Streptococcus (GAS). Combo5 is a non-M protein-based vaccine that provides protection against GAS skin infection in mice and reduces the severity of pharyngitis in nonhuman primates. However, Combo5 with the addition of aluminum hydroxide (alum) as an adjuvant failed to protect against invasive GAS infection of mice. Here, we show that formulation of Combo5 with adjuvants containing saponin QS21 significantly improves protective efficacy, even though all 7 adjuvants tested generated high antigen-specific IgG antibody titers, including alum. Detailed characterization of Combo5 formulated with SMQ adjuvant, a squalene-in-water emulsion containing a TLR4 agonist and QS21, showed significant differences from the results obtained with alum in IgG subclasses generated following immunization, with an absence of GAS opsonizing antibodies. SMQ, but not alum, generated strong interleukin-6 (IL-6), gamma interferon (IFN-γ), and tumor necrosis alpha (TNF-α) responses. This work highlights the importance of adjuvant selection for non-M protein-based GAS vaccines to optimize immune responses and protective efficacy. IMPORTANCE Availability of a group A Streptococcus vaccine remains an unmet public health need. Here, we tested different adjuvant formulations to improve the protective efficacy of non-M protein vaccine Combo5 in an invasive disease model. We show that novel adjuvants can dramatically shape the type of immune response developed following immunization with Combo5 and significantly improve protection. In addition, protection afforded by Combo5 is not mediated by opsonizing antibodies, believed to be the main correlate of protection against GAS infections. Overall, this report highlights the importance of adjuvant selection in raising protective immune responses against GAS invasive infection. Adjuvants that can provide a more balanced Th1/Th2-type response may be required to optimize protection of GAS vaccines, particularly those based on non-M protein antigens.

scholarly journals Chemical and Immunological Characteristics of Aluminum-Based, Oil-Water Emulsion, and Bacterial-Origin Adjuvants

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Susana Martiñón ◽  
Angel Cisneros ◽  
Sergio Villicaña ◽  
Ricardo Hernández-Miramontes ◽  
Edgar Mixcoha ◽  
...  
Keyword(s):  
Immune Response ◽  
Immune Responses ◽  
Lipid A ◽  
Humoral Response ◽  
Main Concern ◽  
Protein Antigens ◽  
Water Emulsion ◽  
Bacterial Origin ◽  
Monophosphoryl Lipid A ◽  
Oil Water

Adjuvants are a diverse family of substances whose main objective is to increase the strength, quality, and duration of the immune response caused by vaccines. The most commonly used adjuvants are aluminum-based, oil-water emulsion, and bacterial-origin adjuvants. In this paper, we will discuss how the election of adjuvants is important for the adjuvant-mediated induction of immunity for different types of vaccines. Aluminum-based adjuvants are the most commonly used, the safest, and have the best efficacy, due to the triggering of a strong humoral response, albeit generating a weak induction of cell-mediated immune response. Freund’s adjuvant is the most widely used oil-water emulsion adjuvant in animal trials; it stimulates inflammation and causes aggregation and precipitation of soluble protein antigens that facilitate the uptake by antigen-presenting cells (APCs). Adjuvants of bacterial origin, such as flagellin,E. colimembranes, and monophosphoryl lipid A (MLA), are known to potentiate immune responses, but their safety and risks are the main concern of their clinical use. This minireview summarizes the mechanisms that classic and novel adjuvants produce to stimulate immune responses.

FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model

2014 ◽  
Vol 16 (5) ◽  
pp. 409-418 ◽  
Author(s):  
Cuiqing Ma ◽  
Zheng Liu ◽  
Wenjian Li ◽  
Xuesong Qian ◽  
Song Zhang ◽  
...  
Keyword(s):  
Mouse Model ◽  
Immune Responses ◽  
Group A Streptococcus ◽  
M Protein ◽  
Epitope Vaccine ◽  
Group A

scholarly journals Expression of Heterologous Antigens in Commensal Neisseria spp.: Preservation of Conformational Epitopes with Vaccine Potential

2004 ◽  
Vol 72 (11) ◽  
pp. 6511-6518 ◽  
Author(s):  
Clíona A. O'Dwyer ◽  
Karen Reddin ◽  
Denis Martin ◽  
Stephen C. Taylor ◽  
Andrew R. Gorringe ◽  
...  
Keyword(s):  
Membrane Protein ◽  
Outer Membrane ◽  
Meningococcal Disease ◽  
Protective Efficacy ◽  
Membrane Vesicles ◽  
Outer Membrane Vesicles ◽  
Heterologous Proteins ◽  
Protein Vaccine ◽  
Native Conformation ◽  
Protein Antigens

ABSTRACT Commensal neisseriae share with Neisseria meningitidis (meningococcus) a tendency towards overproduction of the bacterial outer envelope, leading to the formation and release during growth of outer membrane vesicles (OMVs). OMVs from both meningococci and commensal neisseriae have shown promise as vaccines to protect against meningococcal disease. We report here the successful expression at high levels of heterologous proteins in commensal neisseriae and the display, in its native conformation, of one meningococcal outer membrane protein vaccine candidate, NspA, in OMVs prepared from such a recombinant Neisseria flavescens strain. These NspA-containing OMVs conferred protection against otherwise lethal intraperitoneal challenge of mice with N. meningitidis serogroup B, and sera raised against them mediated opsonophagocytosis of meningococcal strains expressing this antigen. This development promises to facilitate the design of novel vaccines containing membrane protein antigens that are otherwise difficult to present in native conformation that provide cross-protective efficacy in the prevention of meningococcal disease.

scholarly journals Protective Study with a Group A Streptococcal M Protein Vaccine. INFECTIVITY CHALLENGE OF HUMAN VOLUNTEERS

1973 ◽  
Vol 52 (8) ◽  
pp. 1885-1892 ◽  
Author(s):  
Eugene N. Fox ◽  
Robert H. Waldman ◽  
Masako K. Wittner ◽  
Arthur A. Mauceri ◽  
Albert Dorfman
Keyword(s):  
M Protein ◽  
Protein Vaccine ◽  
Streptococcal M Protein ◽  
Human Volunteers ◽  
Group A

scholarly journals Multivalent Group A Streptococcal Vaccine Elicits Bactericidal Antibodies against Variant M Subtypes

2005 ◽  
Vol 12 (7) ◽  
pp. 833-836 ◽  
Author(s):  
James B. Dale ◽  
Thomas Penfound ◽  
Edna Y. Chiang ◽  
Valerie Long ◽  
Stanford T. Shulman ◽  
...  
Keyword(s):  
Wide Spectrum ◽  
Epidemiologic Studies ◽  
M Protein ◽  
Group A Streptococci ◽  
Protein Vaccine ◽  
Amino Terminal ◽  
M Proteins ◽  
Group A ◽  
Clinical Illness

ABSTRACT Group A streptococci cause a wide spectrum of clinical illness. One of several strategies for vaccine prevention of these infections is based on the type-specific M protein epitopes. A multivalent M protein-based vaccine containing type-specific determinants from 26 different M serotypes is now in clinical trials. Recent epidemiologic studies have shown that, within some serotypes, the amino-terminal M protein sequence may show natural variation, giving rise to subtypes. This raises the possibility that vaccine-induced antibodies against the parent type may not be as effective in promoting bactericidal killing of variant subtypes. In the present study we used rabbit antisera against the 26-valent M protein-based vaccine in bactericidal tests against M1, M3, and M5 streptococci, which were represented by multiple subtypes. We show that the vaccine antibodies effectively promoted in vitro bactericidal activity despite the fact that the M proteins contained naturally occurring variant sequences in the regions corresponding to the vaccine sequence. Our results show that the variant M proteins generally do not result in significant differences in opsonization promoted by rabbit antisera raised against the 26-valent vaccine, suggesting that a multivalent M protein vaccine may not permit variant subtypes of group A streptococci to escape in a highly immunized population.

scholarly journals Inverse Relation between Disease Severity and Expression of the Streptococcal Cysteine Protease, SpeB, among Clonal M1T1 Isolates Recovered from Invasive Group A Streptococcal Infection Cases

2000 ◽  
Vol 68 (11) ◽  
pp. 6362-6369 ◽  
Author(s):  
Rita G. Kansal ◽  
Allison McGeer ◽  
Donald E. Low ◽  
Anna Norrby-Teglund ◽  
Malak Kotb
Keyword(s):  
Cysteine Protease ◽  
Protease Activity ◽  
Invasive Disease ◽  
M Protein ◽  
Streptococcal Toxic Shock Syndrome ◽  
Invasive Infection ◽  
Cysteine Protease Activity ◽  
Invasive Infections ◽  
Group A ◽  
High Degree

ABSTRACT The streptococcal cysteine protease (SpeB) is one of the major virulence factors produced by group A streptococci (GAS). In this study we investigated if differences exist in SpeB production by clonally related M1T1 clinical isolates derived from patients with invasive infections. Twenty-nine of these isolates were from nonsevere cases and 48 were from severe cases, including streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis (NF) cases. The expression and amount of the 28-kDa SpeB protein produced were determined by quantitative Western blotting, and protease activity was measured by a fluorescent enzymatic assay. A high degree of variation in SpeB expression was seen among the isolates, and this variation seemed to correlate with the severity and/or clinical manifestation of the invasive infection. The mean amount of 28-kDa SpeB protein and cysteine protease activity produced by isolates from nonsevere cases was significantly higher than that from STSS cases (P = 0.001). This difference was partly due to the fact that 41% of STSS isolates produced little or no SpeB compared to only 14% of isolates recovered in nonsevere cases. Moreover, the cysteine protease activity among those isolates that expressed SpeB was significantly lower for STSS isolates than for isolates from nonsevere cases (P = 0.001). Increased SpeB production was also inversely correlated with intact M protein expression, and inhibition of cysteine protease activity blocked the cleavage of the surface M protein. Together, the data support the existence of both an “on-off” and a posttranslational regulatory mechanism(s) controlling SpeB production, and they suggest that isolates with the speB gene in the “off” state are more likely to spare the surface M protein and to be isolated from cases of severe rather than nonsevere invasive infection. These findings may have important implications for the role of SpeB in host-pathogen interactions via regulation of the expression of GAS virulence genes and the severity of invasive disease.

scholarly journals Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis

2015 ◽  
Vol 22 (9) ◽  
pp. 1033-1039 ◽  
Author(s):  
Ola H. Negm ◽  
Mohamed R. Hamed ◽  
Elizabeth M. Dilnot ◽  
Clifford C. Shone ◽  
Izabela Marszalowska ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Immune Responses ◽  
Protein Microarray ◽  
Enzyme Linked Immunosorbent Assay ◽  
Protein Antigens ◽  
Igg Antibody ◽  
Content Type ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Specific Antigens

ABSTRACTClostridium difficileis an anaerobic, Gram-positive, and spore-forming bacterium that is the leading worldwide infective cause of hospital-acquired and antibiotic-associated diarrhea. Several studies have reported associations between humoral immunity and the clinical course ofC. difficileinfection (CDI). Host humoral immune responses are determined using conventional enzyme-linked immunosorbent assay (ELISA) techniques. Herein, we report the first use of a novel protein microarray assay to determine systemic IgG antibody responses against a panel of highly purifiedC. difficile-specific antigens, including native toxins A and B (TcdA and TcdB, respectively), recombinant fragments of toxins A and B (TxA4 and TxB4, respectively), ribotype-specific surface layer proteins (SLPs; 001, 002, 027), and control proteins (tetanus toxoid andCandida albicans). Microarrays were probed with sera from a total of 327 individuals with CDI, cystic fibrosis without diarrhea, and healthy controls. For all antigens, precision profiles demonstrated <10% coefficient of variation (CV). Significant correlation was observed between microarray and ELISA in the quantification of antitoxin A and antitoxin B IgG. These results indicate that microarray is a suitable assay for defining humoral immune responses toC. difficileprotein antigens and may have potential advantages in throughput, convenience, and cost.

scholarly journals Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines

2012 ◽  
Vol 19 (10) ◽  
pp. 1633-1640 ◽  
Author(s):  
Christopher B. Fox ◽  
Susan L. Baldwin ◽  
Thomas S. Vedvick ◽  
Evelina Angov ◽  
Steven G. Reed
Keyword(s):  
Immune Responses ◽  
Protective Efficacy ◽  
Small Animal ◽  
Vaccine Antigen ◽  
Dose Titration ◽  
Water Emulsion ◽  
Oil Emulsion ◽  
Malaria Vaccines ◽  
Tlr4 Agonist ◽  
Oil In Water Emulsion

ABSTRACTNew malaria vaccines are urgently needed to improve vaccine protective efficacy. PfCelTOS is a recombinant malaria vaccine antigen that has shown protective efficacy in a small-animal challenge model when combined with a water-in-oil emulsion adjuvant (Montanide ISA 720). In this report, we show that PfCelTOS vaccines containing GLA-SE (a stable oil-in-water emulsion combined with a Toll-like receptor 4 [TLR4] agonist) elicit strong Th1-type immune responses in BALB/c mice. These responses include higher antigen-specific IgG2a antibody titers and more gamma interferon (IFN-γ) production than those seen with a PfCelTOS vaccine containing Montanide ISA 720. Furthermore, reducing the emulsion dose from 2% to 1% or 0.5% (vol/vol) squalene in GLA-SE did not compromise immunogenicity. Emulsion dose titration in the absence of formulated GLA caused some reduction in humoral and cellular immune responses compared to those with the 2% squalene emulsion dose.

Sign in / Sign up

Export Citation Format

Share Document